Nephrotoxicity in mice after repeated imaging using 111In- labeled peptides

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 973-977

  Melis, Marleen ^a   Vegt, Erik ^b   Konijnenberg, Mark W ^c   De Visser, Monique ^a   Bijster, Magda ^a   Vermeij, Marcel ^a   Krenning, Eric P ^a   Boerman, Otto C ^c   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDTRONIC INC   (United States)

Author keywords

111In; Dosimetry; Nephrotoxicity; Radiolabeled peptide; Renal reabsorption

Indexed keywords

EXENDIN 4; INDIUM 111; MEGALIN; NEUROTENSIN; OCTREOTIDE; PENTETIC ACID; PEPTIDE; DIAGNOSTIC AGENT; INDIUM; VENOM;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; FEMALE; HISTOLOGY; ISOTOPE LABELING; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; INJECTION; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION EXPOSURE; RISK; TIME;

ANIMALS; FEMALE; INDIUM RADIOISOTOPES; INJECTIONS; KIDNEY; LDL-RECEPTOR RELATED PROTEIN 2; MALE; MICE; ORGAN SPECIFICITY; PENTETIC ACID; PEPTIDES; RADIATION DOSAGE; RISK; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VENOMS;

EID: 77953949767     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.074310     Document Type: Article

References (20)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
2. van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
3. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122.
4. Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132.
5. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2005;32:1288-1295.
6. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
7. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
8. 111In-DTPA-octreotide. J Nucl Med. 2005;46:1696-1700.
9. Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136-1143.
10. Vegt E, Melis M, Eek A, et al. Megalin plays an important role in the renal uptake of various radiolabelled peptides: studies in megalin-deficient mice [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2):S231.
11. Leheste JR, Melsen F, Wellner M, et al. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J. 2003;17:247-249.
12. Melis M, Krenning EP, Bernard BF, et al. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. Nucl Med Biol. 2007;34:633-641.
13. 111In) NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-2033.
14. Hindorf C, Ljungberg M, Strand SE. Evaluation of parameters influencing S values in mouse dosimetry. J Nucl Med. 2004;45:1960-1965.
15. 3]octreotate in rats. Eur J Nucl Med Mol Imaging. 2007;34:219-227.
16. 99mTc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm. 2007;22:40-49.
17. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
18. Bitar A, Lisbona A, Bardies M. S-factor calculations for mouse models using Monte-Carlo simulations. Q J Nucl Med Mol Imaging. 2007;51:343-351.
19. Stabin MG, Peterson TE, Holburn GE, Emmons MA. Voxel-based mouse and rat models for internal dose calculations. J Nucl Med. 2006;47:655-659.
20. 111In-DTPA] octreotide. J Nucl Med. 2004;45:1168-1171.